Our Team

He designed, built, and lead the commercialization of ArtVentive EOS™ device. Dr. Rudakov holds 34 patents related to the EOS™ family of devices.

Prior to starting ArtVentive Medical Group Dr. Rudakov spent more than 25 years in corporate management, R&D, and engineering.

He has held several executive management and leading R&D positions with international corporations, including Booz Allen & Hamilton, and various medical device startup companies.

Dr. Rudakov pioneered the development and commercialization of various cardiovascular devices, including a stent graft for coronary artery bypass surgery and a unique neurovascular device for the treatment of intracranial aneurysms.

He has developed the Coronary Stent that has been sold to Goodman Corporation of Japan and approved as a Goodman stent. His later works on future coronary stent designs were followed by obtaining the CE Mark for commercial use of the device in Southeast Asia.

Dr. Rudakov holds PhD from Moscow Aviation Institute in Mechanical Engineering, Design Management, and Optimization and he is a graduate of Duke University, Fuqua School of Business, N.C. Business Executive Program.

Prior to joining ArtVentive, Bill served as the global strategist at Abbott Vascular, a multi-billion-dollar division of Abbott. There he was responsible for overall strategy, annual/long range planning and market intelligence for its wide range of coronary and endovascular products.

 As Global Director of Endovascular Marketing at Abbott from 2017-2019 he had overall responsibility for the high growth Endovascular business; including peripheral vascular products, vessel closure devices, guidewires and embolization plugs.

Mr. Olson was President and CEO of ACT, an electrophysiology catheter company now owned by Medtronic, and co-founder and CEO of Sawtooth Labs/Avinger with Dr. John B. Simpson.  He also served as a Vice President of Corporate Development at FoxHollow Technologies, also now owned by Medtronic. 

His broad experience also includes direct sales for Guidant's Cardiac Rhythm Management division (now Boston Scientific), strategy and operations consulting at Deloitte Consulting and was a Six Sigma Blackbelt at GE Medical. 

Mr. Olson holds an MBA from Harvard Business School and undergraduate degrees from Boston College and lives in the SF Bay Area.

Mr. Reithinger is the Founder and President of Eventus Advisory Group, LLC, a CFO-services firm that specializes in capital advisory and SEC compliance for publicly-traded and emerging growth companies. He is also the President of Eventus Consulting, P.C., a registered CPA firm in Arizona. Mr. Reithinger is an experienced CFO with over 22 years of diversified practice in a broad range of industries including life sciences, consumer products, mining, energy services and digital media. Mr. Reithinger has successfully created initiatives to streamline accounting processes and SEC compliance, develop capital markets strategies, restructure and optimize operations and spearhead due diligence for financings and acquisitions. He has strong leadership and administrative skills, experience in building efficient processes, and managing and developing accounting and finance staff.

Since August 2014, Mr. Reithinger has served as the CFO of Orgenesis Inc., a publicly-traded cell therapy and regenerative medicine company with a technology focused on curing Type 1 diabetes. Prior to forming Eventus Advisory Group, LLC in December 2009, Mr. Reithinger served in various executive management positions including COO & CFO of New Leaf Brands, Inc., a branded beverage company, CEO of Nutritional Specialties, Inc., a nutritional supplement company (that was acquired by Nutraceutical International, Inc. NASDAQ: NUTR), and Chairman, CEO & President of Baywood International, Inc., a publicly-traded nutraceutical company. Prior to that, Mr. Reithinger worked for Bank of America. Mr. Reithinger earned a B.S. in Accounting from the University of Arizona and is a Certified Public Accountant. He is a Member of the American Institute of Certified Public Accountants and the Arizona Society of Certified Public Accountants.

Anil has over 25 years of experience in the medical device industry in the areas of regulatory affairs, clinical affairs, quality assurance, quality engineering, and manufacturing engineering 

He has a successful track record obtaining 510(k) clearances, PMA and IDE approvals for Class I, II and III medical devices in the fields of respiratory therapy, urology, vascular, cardiovascular, orthopedics and neurology 

He has extensive experience in analyzing and funding public and private companies and has assisted with corporate restructurings, public and private equity financings, mergers and acquisitions, debt and equity financings, due diligence, and litigation claims. Mikhail previously worked with a prestigious New York based special situations capital markets firm focusing on middle market transactions.

Mikhail holds a Bachelor’s degree in Business Administration from Winona State University together with a J. D. and an LL.M. in Taxation from the University of Denver. Mikhail is admitted to practice law in New York, Washington D.C., and Colorado. He is also admitted to practice law in the United States Tax Court.

Dr. Venbrux received his Doctorate of Medicine from the University of Washington’s School of Medicine and received his fellowship at the Walter Reed Army Medical Center, Washington, DC, in the department of Angiography and Interventional Radiology.

Dr. Venbrux has served as chairperson of the Cardiovascular Radiology Council of the American Heart Association since 2001.

The Erasmus Medical Center has become leading in hepatopancreatic biliary oncologic patient care and, therefore, the Interventional Radiology is concentrated around complex liver interventions such as thermal ablations, radio-embolization, and portal vein embolization. Besides, his expertise follows arterial and venous endovascular procedures such as pelvic congestion syndrome and chronic venous occlusive disease. Adriaan collaborates intensively with the “Image Guidance in Interventions and Therapy” research theme of the Biomedical Imaging Group Rotterdam, supervising several PhD students with projects in the field. This research specifically focuses on improving image guidance by integrating pre-operative image information in the interventional situation for cardiovascular and soft tissue applications.

He has written and co-authored over 100 publications and presentations, in addition to being a member of a number of Scientific Advisory Boards leading corporations within the global medical community. He is a member of the Strategic Planning Committee for the University of Rochester Medical School. He also teaches gastroenterology and advanced endoscopy in developing countries.

Dr. Akman received his Doctor of Medicine and Masters in Business Administration May 2003 from Tufts University School of Medicine in Boston prior to his Fellowship in Vascular and Interventional Radiology at Johns Hopkins Hospital in Baltimore, Maryland. Dr. Akman has written 13 publications, educational exhibits, and presentations, in addition to being a member of the Society of Interventional Radiology.